10-Q: Bioethics, Ltd. Reports Third Quarter 2024 Results, Cites Ongoing Losses and Merger Agreement

Bioethics, Ltd., a shell company, reported a net loss of $128,668 for the nine months ended September 30, 2024, and is pursuing a merger with SILQ Technologies Corporation.

Summary

• Bioethics, Ltd. is a shell company with no active business operations, seeking acquisition or participation opportunities.
• The company reported a net loss of $128,668 for the nine months ended September 30, 2024, compared to a net loss of $72,746 for the same period in 2023.
• General and administrative expenses increased to $89,483 for the nine months ended September 30, 2024, from $36,843 in the prior year.
• The company's working capital deficit was $862,933 as of September 30, 2024, compared to $776,265 at the end of 2023.
• As of September 30, 2024, the company had $17,153 in cash and cash equivalents, up from $138 at the end of 2023.
• Total current liabilities were $880,086 as of September 30, 2024, compared to $776,403 at the end of 2023.
• The company has an accumulated deficit of $1,406,547 since its inception.
• Bioethics, Ltd. entered into a merger agreement with SILQ Technologies Corporation on or about September 20, 2024, but there is no assurance the merger will be completed.
• The company issued 620,000 shares of Series A Preferred Stock for $62,000, receiving $42,000 in cash and $20,000 as a subscription receivable.
• The company's financial statements indicate a going concern issue due to ongoing losses and lack of operations.

Sentiment

Score: 3

Explanation: The document indicates significant financial challenges, including ongoing losses, a large working capital deficit, and ineffective internal controls. While the company is pursuing a merger, there is no guarantee of success, and the overall outlook is negative.

Positives

• Cash and cash equivalents increased to $17,153 as of September 30, 2024, from $138 at the end of 2023.
• The company raised $42,000 in cash through the issuance of preferred stock.
• The company is actively pursuing a merger with SILQ Technologies Corporation.

Negatives

• The company reported a net loss of $128,668 for the nine months ended September 30, 2024.
• The company has a significant working capital deficit of $862,933.
• The company has an accumulated deficit of $1,406,547 since inception.
• The company's internal controls over financial reporting were deemed not effective.
• The company has no ongoing operations and is considered a shell company.
• There is no assurance that the merger with SILQ Technologies Corporation will be completed.
• The company has a number of outstanding promissory notes, some of which are in default.

Risks

• The company's ability to continue as a going concern is in doubt due to ongoing losses and lack of operations.
• There is no assurance that the company will be able to obtain additional debt or equity capital.
• The merger with SILQ Technologies Corporation may not be consummated.
• The company's internal controls over financial reporting are not effective.
• The company is dependent on external funding sources to cover operating costs.
• The company has a significant amount of debt, some of which is in default.

Future Outlook

The company is seeking business opportunities for acquisition or participation and is currently pursuing a merger with SILQ Technologies Corporation, but there is no assurance that the merger will be completed. The company will require additional funds to pay the costs of negotiating and completing any acquisition.

Management Comments

• Management believes that all adjustments necessary to present fairly the financial position, results of operations, and cash flows for the nine months ended September 30, 2024 and 2023 have been made.
• Management is proposing to raise any necessary additional funds not provided by operations through loans, additional sales of its common stock, or through a possible business combination.
• Management concluded that the company's disclosure controls and procedures were not effective as of September 30, 2024.
• Management concluded that the company's internal control over financial reporting was not effective as of September 30, 2024.

Industry Context

As a shell company with no active operations, Bioethics, Ltd.'s situation is not directly comparable to companies with ongoing business activities. The company's focus on finding a merger or acquisition target is common among shell companies, which often seek to leverage their public listing status to acquire private businesses.

Comparison to Industry Standards

• Bioethics, Ltd. is a shell company and does not have any direct industry comparables in terms of operations.
• The company's financial performance is not comparable to companies with ongoing operations, as it has no revenue and significant losses.
• The company's reliance on external funding and its pursuit of a merger are typical characteristics of shell companies.
• The company's internal control deficiencies are a concern and would not meet the standards of most operating companies.

Related Party Transactions

• The company has related party transactions including rent payments to its President and promissory notes with related parties.

Stakeholder Impact

• Shareholders face significant risk due to the company's ongoing losses and lack of operations.
• Employees are not directly impacted as the company has no ongoing operations.
• Creditors face risk due to the company's significant debt and potential inability to repay.
• The merger with SILQ Technologies Corporation could have a significant impact on all stakeholders if completed.

Next Steps

• The company will continue to seek business opportunities for acquisition or participation.
• The company will attempt to complete the merger with SILQ Technologies Corporation.
• The company will need to raise additional capital to fund operations and any potential acquisition.
• The company will need to address the deficiencies in its internal controls over financial reporting.

Key Dates

Keywords

shell company, merger, acquisition, financial statements, net loss, working capital deficit, promissory notes, internal controls, going concern, preferred stock